

**PARADIGM TO PRESENT AT 7TH ANNUAL TRUIST SECURITIES
LIFE SCIENCES SUMMIT**

Paradigm Biopharmaceuticals Ltd (ASX: PAR) a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, is pleased to announce it has been invited to present at the 7th Annual Truist Securities Life Science Summit. The conference is being held virtually on May 4-5 (US) with Paradigm participating in a 40-minute fire side chat with one of Truist's healthcare analysts. During the event, members of the Paradigm executive leadership will engage in 1x1 investor meetings.

Presentation Details:

Event: 7th Annual Truist Securities Life Sciences Summit.

Time: AUS: Wednesday 5th May, 6:20am (AEST)

US: Tuesday 4th May, 4:20pm (Eastern)

Link: <https://kvgo.com/life-sciences-summit/paradigm-biopharmaceuticals-may-2021>

Note: The presentation's replay link will be the same as the live link above. Please allow up to 12 hours after the completion of the presentation for the replay to be made available.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise Pentosan Polysulfate Sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection or genetic predisposition.

Authorised for release by Paul Rennie, CEO & Interim Chairman.

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com

For personal use only